MYC and non-small cell lung carcinoma: Studies have shown SRA737 to be an effective CHK1 inhibitor in the preclinical setting, abrogating etoposide-mediated G2/M arrest in HT-29 cells, with preclinical activity also being demonstrated in RAS NSCLC and Eμ-MYC driven B-cell lymphoma models [33].